Complexes of actinide metal ions with specific ligands are extensively used for many applications in the field of chelation therapy. The most frequently used ligands for the targeted α-therapy are poly-bidentate and employ hard basic moieties, such as HOPO (hydroxy-pyridinone).
Encouraged by the high affinity of the 1,2-HOPO ligands towards actinides and, accordingly, their impressive potential to be used as sequestering agents for such metal ions, we decided to develop a series of new chelators for actinides, which will be used for therapeutic applications (e.g. targeted α-therapy and actinide de-corporation).
These new chelators are based on a dendritic backbone and carry peripheral 6-carboxamide-1,2-HOPO chelating units (Figure 1). The dendritic architecture produces, in the case of the second generation G2 dendron, a tetra-HOPO arrangement essential for a successful sequestering of actinide metal ions, whose preferred coordination numbers are 6 or 8. The carboxamide function of the chelators assists in adjusting the pKa of the free ligand to form stable complexes under physiological conditions and serves as a connector to the backbone. The non-dendritic analogue (G0) and the first generation dendron (G1) serve as models for the developing of the methodology for the synthesis of the higher generation target.